cyclophosphamide,rituximab,vincristine,doxorubicin,prednisone,polatuzumab vedotin
roche
['dlbcl', 'pola', 'cml', 'polarix', 'genentech']
exciting times at #17icml! learn more about the descriptive analysis of the polarix study in abstract 318. this poster delves into the cause of death and prognosis of patients with primary refractory disease, and the prognosis of patients reaching pfs24. #dlbcl #hemetwitter
Sharing the latest scientific, medical, and clinical trial information with US healthcare professionals. View our community guidelines here: https://t.co/JdZjiL3i8N